SynAct Pharma (SYNACT) Company presentation summary

Business overview and strategy

• Focuses on pro-resolution therapies for immune disorders, with lead compound resomelagon in advanced clinical development for rheumatoid arthritis and viral infections.

• Publicly traded on NASDAQ Stockholm, with funding secured into Q3 2027 and a highly experienced management team.

• Pursues a dual development strategy targeting both chronic autoimmune and acute inflammatory conditions.

• Pipeline includes next-generation peptide-based therapies and host-directed antivirals in clinical and preclinical stages.

• Active business development aims to position resomelagon as a 'pipeline-in-a-product' with blockbuster potential.

Lead compound and mechanism of action

• Resomelagon is a novel biased melanocortin receptor agonist that modulates M1/M2 macrophages, reducing pro-inflammatory cytokines and promoting resolution pathways.

• Demonstrates anti-inflammatory effects without stimulating melanogenesis, with potential as a first-in-class, non-suppressive therapy.

• Enables macrophage modulation and may be effective as an add-on therapy across multiple indications.

Clinical development and trial results

• Phase 2b ADVANCE study in newly diagnosed, treatment-naive RA patients is ongoing, with topline results expected to inform Phase 3 planning.

• Phase 2a and EXPAND studies showed significant improvements in disease activity and response rates in RA, with a favorable safety profile.

• Host-directed therapy in viral infections demonstrated faster respiratory recovery and reduced hospital stays in severe COVID-19 patients.

• Ongoing Phase 2 studies target respiratory viral infections and dengue, with recruitment aligned to epidemic cycles.